DB:YBOC

Stock Analysis Report

Executive Summary

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Tenax Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: YBOC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.9%

YBOC

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

1.9%

YBOC

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: YBOC underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: YBOC underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

YBOCIndustryMarket
7 Day-0.9%-4.1%-5.7%
30 Day-12.1%-8.2%-5.7%
90 Day0%-2.0%-3.6%
1 Year1.9%1.9%4.0%3.7%9.3%6.1%
3 Year-91.8%-91.8%38.2%36.7%8.9%-0.7%
5 Year-98.1%-98.1%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Tenax Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Tenax Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: YBOC (€1.09) is trading below our estimate of fair value (€50.26)

Significantly Below Fair Value: YBOC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: YBOC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: YBOC is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate YBOC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: YBOC is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Tenax Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-49.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: YBOC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: YBOC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: YBOC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if YBOC's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if YBOC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if YBOC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tenax Therapeutics performed over the past 5 years?

6.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: YBOC is currently unprofitable.

Growing Profit Margin: YBOC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: YBOC is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare YBOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YBOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: YBOC has a negative Return on Equity (-119.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Tenax Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: YBOC's short term assets ($7.6M) exceed its short term liabilities ($1.1M).

Long Term Liabilities: YBOC's short term assets ($7.6M) exceed its long term liabilities ($108.4K).


Debt to Equity History and Analysis

Debt Level: YBOC is debt free.

Reducing Debt: YBOC has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.


Balance Sheet

Inventory Level: YBOC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if YBOC's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YBOC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: YBOC has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.8% each year.


Next Steps

Dividend

What is Tenax Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate YBOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate YBOC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if YBOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if YBOC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of YBOC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Tony DiTonno (71yo)

1.7yrs

Tenure

US$645,766

Compensation

Mr. Anthony A. DiTonno, also known as Tony, has been Chief Executive Officer of Tenax Therapeutics, Inc. since June 1, 2018. From January 2013 until May 31, 2018, Mr. DiTonno served as Chief Executive Offi ...


CEO Compensation Analysis

Compensation vs Market: Tony's total compensation ($USD645.77K) is above average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Tony's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Anthony DiTonno
CEO & Director1.7yrsUS$645.77k0.0024% $179.2
Michael Jebsen
President & CFO0yrsUS$855.81k0.43% $32.6k
Nancy J. Hecox
Executive VP of Legal Affairs10.3yrsno datano data
Doug Randall
Executive Vice President of Commercial & Business Operations0yrsno datano data
Douglas Hay
Executive Vice President of Regulatory Affairs0yrsno datano data
John Kelley
Consultant2.8yrsUS$986.55kno data

2.8yrs

Average Tenure

65yo

Average Age

Experienced Management: YBOC's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anthony DiTonno
CEO & Director1.7yrsUS$645.77k0.0024% $179.2
Gerald Proehl
Independent Director5.8yrsUS$62.12k0.022% $1.7k
Ronald Blanck
Independent Chairman8.4yrsUS$68.62k0.016% $1.2k
James Mitchum
Independent Director4.4yrsUS$62.62k0.019% $1.5k
Ross Bullock
Chairman of Medical Advisory Board0yrsno datano data
Joseph Watson
Member of Medical Advisory Board0yrsno datano data
Robert Sladen
Member of Medical Advisory Board0yrsno datano data
Cyril Mazer
Member of Medical Advisory Board0yrsno datano data
Abelardo DeAnda
Member of Medical Advisory Board0yrsno datano data
Stuart Rich
Chairman of Scientific Advisory Board2yrsno datano data

5.8yrs

Average Tenure

68.5yo

Average Age

Experienced Board: YBOC's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 247%.


Top Shareholders

Company Information

Tenax Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tenax Therapeutics, Inc.
  • Ticker: YBOC
  • Exchange: DB
  • Founded: 1967
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.225m
  • Listing Market Cap: US$7.560m
  • Shares outstanding: 6.74m
  • Website: https://www.tenaxthera.com

Number of Employees


Location

  • Tenax Therapeutics, Inc.
  • ONE Copley Parkway
  • Suite 490
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
YBOCDB (Deutsche Boerse AG)YesCommon StockDEEURMar 1993
TENXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1993

Biography

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 20:32
End of Day Share Price2020/02/25 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.